Welcome to our dedicated page for Roivant Sciences SEC filings (Ticker: ROIV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Roivant Sciences Ltd. (Nasdaq: ROIV) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a Bermuda-incorporated biopharmaceutical issuer with common shares listed on The Nasdaq Global Select Market, Roivant files annual reports, quarterly updates, current reports on Form 8-K, proxy statements and other disclosures that describe its business, governance, financial condition and material events.
Through Roivant’s filings, investors can review detailed information on its biopharmaceutical pipeline, including brepocitinib, IMVT-1402, batoclimab and mosliciguat, as well as the activities of subsidiaries such as Priovant Therapeutics, Immunovant, Pulmovant and Genevant. Current reports on Form 8-K have been used to furnish press releases on quarterly financial results, to report positive Phase 3 VALOR data in dermatomyositis, to provide updates on Graves’ disease development at Immunovant, and to disclose authorization of common share repurchase programs.
Roivant’s periodic reports discuss consolidated research and development and general and administrative expenses, share-based compensation, gains and losses from transactions such as the sale of Telavant net assets and the sale of its equity interest in Dermavant, and income or loss from discontinued operations. The company’s definitive proxy statement on Schedule 14A describes its annual general meeting of shareholders, director elections, auditor ratification and advisory votes on executive compensation, and lays out governance and compensation policies.
On Stock Titan, Roivant filings are paired with AI-powered summaries designed to help readers interpret complex documents. Users can quickly see the key points from 10-K and 10-Q reports, understand the significance of 8-K disclosures, and locate information related to capital allocation, clinical programs and subsidiary activities. Form 4 and other ownership-related filings, when available, can be used to track insider transactions and equity incentives disclosed by the company.
Roivant Sciences Ltd. insider plans to sell 200,000 common shares under Rule 144. The shares are to be sold through Rockefeller Financial LLC on NASDAQ around 01/12/2026, with an aggregate market value of 4,383,694.07 and 695,491,615 common shares outstanding. The 200,000 shares were acquired on 01/12/2026 by exercising options originally granted on 04/20/2022, with payment made by wire.
Over the prior three months, the same seller, Eric Venker (c/o Roivant Sciences Ltd., London), completed multiple open-market sales of Roivant common shares. Individual transactions included 414,683 shares sold on 10/15/2025 for 7,021,429.14 and 318,282 shares sold on 10/16/2025 for 5,425,645.04, along with several other sales ranging from 7,051 to 200,000 shares. By signing the notice, the seller represents they do not know any undisclosed material adverse information about Roivant’s operations.
Roivant Sciences Ltd. director Dan Gold reported multiple sales of the company’s Common Shares made indirectly through QVT Financial Investment Cayman Ltd. On 12/16/2025, QVT FIC sold 275,000 Common Shares at a price of $22.93 per share and 642,282 Common Shares at $23.08 per share. On 12/17/2025, QVT FIC sold additional blocks of 432,718, 155,076, and 189,538 Common Shares at prices of $23.05, $23.02, and $23.17 per share, respectively.
Following these transactions, QVT FIC is reported to beneficially own 16,353,113 Roivant Common Shares, which are reported as indirectly owned by Gold through his role as one of three directors of QVT FIC. Gold disclaims beneficial ownership of these securities beyond his pecuniary interest.
Roivant Sciences Ltd. insider trading report: CEO and director Matthew Gline reported multiple transactions in Roivant common shares on 12/15/2025. He exercised stock options to buy 234,096 shares at $4.06 and a total of 3,636,563 shares at $12.68, then reported sales of 230,357, 566,116 and 943,527 shares at $21.68 per share. Additional share dispositions reflect “net settlement” of options to cover exercise prices. After these transactions, he reported beneficial ownership of 17,287,081 common shares held directly.
The filing notes that all options expiring in 2026 were exercised, eliminating that option position, and states that Gline has disgorged to Roivant the full amount of disgorgable profits from the sales as required by Section 16(b) of the Exchange Act.
Roivant Sciences director Vivek Ramaswamy reported large stock option exercises and related share sales in December 2025. On 12/11, 12/12 and 12/15, he exercised options at $12.68 per share to acquire 1,869,691, 4,672,724 and 832,453 common shares, respectively. On those same dates he sold 774,142, 1,975,858 and 353,745 shares at weighted average prices of $21.64, $21.96 and $22.05, and additional shares were disposed of through issuer net settlement to cover option exercise costs.
After these transactions, he beneficially owned 33,653,755 common shares directly and 13,357,857 shares indirectly through his spouse. The exercised options would have expired in March 2026 if not exercised and arise from awards that began vesting on December 27, 2019.
Immunovant, Inc. reported an insider transaction by a reporting person who is both a director and a 10% owner. On December 12, 2025, this filer purchased 16,666,666 shares of Immunovant common stock at $21 per share. Following the transaction, the filer directly beneficially owned 113,317,007 Immunovant shares. The filer is considered a director by deputization because senior executives of Roivant Sciences, Inc., a subsidiary of the reporting person, currently serve on Immunovant’s board on its behalf.
Roivant Sciences Ltd. officer Eric Venker, President & Immunovant CEO, reported equity transactions dated December 9, 2025. He exercised stock options to acquire 200,000 common shares at an exercise price of $3.85 per share, then sold 200,000 common shares at a weighted average price of $20.85 per share pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
After these transactions, he directly beneficially owned 1,497,908 common shares of Roivant Sciences. He also held 5,876,523 stock options exercisable into common stock at $3.85 per share, from a grant with a vesting commencement date of April 20, 2022 that vests 25% on the first anniversary and the remainder in 36 equal monthly installments, with an expiration date of April 19, 2032.
Roivant Sciences Ltd. (ROIV) reported an insider equity transaction by its Chief Financial Officer. On 11/20/2025, the CFO had 1,235 common shares withheld at a price of $20.27 per share. This was a "net settlement" of previously granted restricted stock units (RSUs) to cover tax withholding obligations when those RSUs vested and were settled.
After this tax-related share withholding, the CFO beneficially owns 388,273 common shares, held directly. The filing indicates this was an administrative equity compensation event, not an open-market purchase or sale.
Roivant Sciences Ltd. insider transaction: A Form 4 reports that officer Eric Venker, President & Immunovant CEO, had 7,051 common shares of Roivant Sciences Ltd. withheld on 11/20/2025 at a price of $20.27 per share. The filing explains this was a "net settlement" of previously granted restricted stock units (RSUs) by the company to cover applicable tax withholding when those RSUs vested and settled.
After this tax-related share withholding, Venker directly beneficially owns 1,497,908 common shares of Roivant Sciences Ltd. This type of transaction does not represent an open-market sale, but rather an administrative step tied to equity compensation vesting.
Roivant Sciences Ltd. (ROIV) director reported multiple indirect sales of common shares on 11/19/2025. The transactions were coded as open-market sales, with blocks of shares sold at prices between $20.16 and $20.25 per share through QVT Financial Investment Cayman Ltd.
Following these sales, the reporting person shows 18,047,727 Roivant common shares beneficially owned on an indirect basis through QVT Financial Investment Cayman Ltd. The filing notes that the individual is a shareholder of that entity but has no voting or investment control over it and expressly disclaims beneficial ownership of the reported shares beyond any pecuniary interest.
Roivant Sciences Ltd. (ROIV) director Dan Gold reported several open‑market sales of the company’s Common Shares on 11/19/2025. Indirectly through QVT Financial Investment Cayman Ltd., he sold 850,000 shares at $20.25, 150,000 shares at $20.20, 125,000 shares at $20.16, and 175,000 shares at $20.24, all coded as sales. Following these transactions, 18,047,727 Common Shares were beneficially owned indirectly, reported as held by QVT Financial Investment Cayman Ltd. The filing notes that Gold is one of three directors of QVT Financial Investment Cayman Ltd., shares voting and investment control over these shares, and disclaims beneficial ownership beyond his pecuniary interest.